- SFB financials may look better than mainstream banks, but their lending operations are quite risky
- We identify three of them based on financials and disclosures
- SFB deposits are good as a diversifier and not as capital protection vehicles
Want a fund that will avoid expensive valuations and yet not leave you with the pain of the long wait for value to work? This fund does just that. Not only that, this fund can replace large-cap funds in your portfolio. Replacing pure large-cap funds with moderate-risk multi-cap funds is a strategy we have been suggesting for a while now. And this multi-cap fund avoids the high-valuation territory that most large-cap funds are prone to.
Invesco India Contra (Invesco Contra) is not a pure-breed value fund. But it satisfies a lay investor’s search for mispriced stocks. It does this at two levels: one, it goes overweight (compared with the benchmark) to capture the opportunity in out-of-fancy sectors. At a stock level, it goes for stocks that are either trading below their fundamental value (clear value case) or are in a turnaround phase or are growth companies that the fund believes are temporarily de-rated. This part is meant to be value.
But then, the fund also holds stocks that were bought as value and later become growth candidates. This last part buttresses the performance of the fund when value underperforms for prolonged periods. This can be 20-30% of the fund’s portfolio.
Invesco Contra is multi-cap in its strategy and is suitable for moderate to high risk investors. The fund has marginally higher volatility than other contra or value funds given that it has up to 30% in growth stocks. It also has close to 30% in mid & small cap stocks. This share is not that much higher than the average for multi-caps, but is still above most other value/contra funds. It does not take cash calls, unlike peers. This also heightens volatility in falling markets.
If your time frame is at least 5-7 years and you are an above-average risk taker, then you can consider holding such this fund along with our earlier call on the Nifty Next 50 index. The fund is part of our Prime Funds list.
Returns as of Feb 14, 2020
Invesco India Contra managed to beat the Nifty 500 TRI (the benchmark we consider for multi caps) as well as category average (multi caps, contra value and dividend yield funds) 100% of the times when three-year returns were rolled daily for an 8-year period. Funds such as Kotak Multicap, Motilal Oswal Multicap 35, Edelweiss Multicap and SBI Magnum Multicap share this feat albeit with very different strategies.
In the above period the fund’s average annualized 3-year returns was 19.7% as opposed to 14.9% average for the above-mentioned categories. The worst 3-year returns over this period was 8% while the category fared at 4%.
Invesco Contra tends to show volatility over shorter time frames and has higher standard deviation. On rolling 1-year returns over the past 3 years the fund beat the benchmark 60% of the times. While this may seem low, peers on an average outperformed the index just 36% of the times. The fund’s downside probability too is not the best, for the same reason mentioned earlier.
Invesco Contra’s portfolio in 2019 had far lower in valuations than its benchmark, the S&P BSE 500. Its portfolio was underperforming in 2019 for 2 reasons: one, value didn’t take off in the narrow rally of large-cap stocks seen in 2019.
Second, the mid and small cap segment continued to correct resulting in poor performance of the fund compared with peers with higher large-cap allocation. This saw funds like Kotak Contra (which has higher large-cap allocation) beat the fund.
In the last 6 months, this trend reversed with the fund gaining 15.5% as opposed to benchmark returns of 11.4%. Value funds delivered lesser, at 9.65% on an average. The graph above will also show you that this rally resulted in its PE moving up.
Invesco Contra’s value-turned growth picks include HDFC Bank, ICICI Bank and Reliance Industries. Others such as Bharti Airtel or Axis Bank, having been picked in lows in September/October 2018, remain relatively attractive in valuations. Invesco Contra has displayed astute value picking traits, be it in the above-mentioned large caps or midcaps such as Apollo Hospital Enterprises, entered in September 2017 (61% stock returns since) or Coromandel International picked in December 2018 (42% stock returns since).
What stokes our interest in the fund at this juncture is the cyclical tilt in its portfolio in terms of energy, automobiles, consumer discretionary and construction besides de-rated pockets of IT and healthcare. This mix ensures that it does not miss on an economic recovery while at the same time, has enough opportunities even if recovery gets delayed. In the financial services space, while the fund may appear overweight overall, it has cut down pockets of banking and instead hiked in financial services. This may also serve it well as there are signs of recovery in quality financials.
Taher Badshah and Amit Ganatra manage this fund. Its AUM as of January 2020 was Rs 4751 crore.
10 thoughts on “Prime Recommendation: A value-conscious fund without the pain of value underperformance”
You may want to update this article as relevant.
Since the time this article was written, Amit Ganatra has been poached by HDFC MF. He now manages HDFC Capital Builder Value Fund. Based on what I understand, Amit Ganatra (managed Invesco Contra from 2012-2020) & Vetri Subramaniam (managed Invesco Contra from 2008-2016) must have had a big role in the stellar performance of the fund.
Would you still recommend Invesco India Contra or you have put it on a “wait & watch” list?
Please check our Prime funds list 🙂 If we had changed our call, you would have heard from us during the quarterly review mails we send out. thanks, Vidya
Madam please comment about HDFC CAPITAL BUILDER VALUE and QUANTUM LONG TERM EQUITY. nobody talks about them now. HDFC capital had a 13 percent cagr for 23 years and then started underperforming. Quantum also had 13 plus returns. Is it time to leave them.
Value tends to underperform for prolonged periods of time. This is not the right tiem to exit. We will be writing about value soon. Do stay tuned.
Hi Ms. Vidhya , this opening statement on performance section ” when three-year returns were rolled daily for an 8-year period” , you have given 100% value to this report. My personal observation with this fund , even though its called contra fund , its portfolio seems to be a growth style rather than contrarian picks such as pharma , power or non ferrous metals . .
Hello Vivek, 100% is the outperformance % over category including all multicaps, value and contra. Also, please note that we have stated that this is not a pure value fund. roughly around 70% is value, rest is value-turned growth. The entire strategy is explained in the analysis. There is value in pockets of cyclicals. It also has commodities and pharma. Value or contrarian need not always come from defesive sectors. thanks, Vidya
Hi Ms Vidya, good to connect in PI. What could be advantages of Direct and regular MF managed by a AMC as an investor?
Hello Sir, thanks. Hope your query was responded through our mail. regards, Vidya
When showing year on year trends why not use 5y or more- to cover long term trend
Hello, We do that analysis as well. But we don’t show it for 2 main reasons: one, the 5-year rolling trend can mislead an investoreven when the last 2 years of rolling 5 year returns show a steady deterioration. Classic example being pure value funds like Value Discovery which shows a higher % of outperformance over 5 year periods but steadily underperforming in recent years. Second, when we run 5-year returns you need about 2500 data points. Many peers don’t have it, so we will be doing comparison with fewer peers. thanks, Vidya
Comments are closed.